A5057382090- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Cancer Genomics and Diagnostics
- Blood groups and transfusion
- Immune Cell Function and Interaction
- Immune cells in cancer
- Lung Cancer Treatments and Mutations
- T-cell and B-cell Immunology
- Biosimilars and Bioanalytical Methods
- Chronic Myeloid Leukemia Treatments
- Cancer, Hypoxia, and Metabolism
- PARP inhibition in cancer therapy
- Advanced Breast Cancer Therapies
- Phagocytosis and Immune Regulation
- Toxin Mechanisms and Immunotoxins
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chemical Reactions and Isotopes
- Galectins and Cancer Biology
- Radiomics and Machine Learning in Medical Imaging
- Cancer Cells and Metastasis
- Medical Imaging Techniques and Applications
- Ovarian cancer diagnosis and treatment
Grand Charleroi Hospital
2016-2025
Institute of Pathology and Genetics
2016-2024
Cornell University
2023
Kettering University
2022
de Duve Institute
2016-2022
Memorial Sloan Kettering Cancer Center
2020-2022
UCLouvain
2017
Cliniques Universitaires Saint-Luc
2016
Abstract The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making patients with advanced cancers. This multi-center enrolled 872 from 12 hospitals. CGP was performed on tumor tissues a standardized panel (523 genes) across nine laboratories success 93% and median turnaround time 29 days. Actionable markers were identified 81% patients, substantially higher than 21%...
2508 Background: DF1001 is a first in class, Tri-specific, NK cell Engager Therapy (TriNKET), that uses HER2 as an anchor to modulate innate and adaptive immunity. redirects both CD8 T cells reprogram the tumor microenvironment, turning cold tumors hot. DF1001-001 (NCT04143711) ongoing phase I/II, human study investigating safety, tolerability, clinical biologic activity of DF1001. The pharmacokinetic (PK), pharmacodynamic (PD) efficacy data from 1 monotherapy escalation safety/PK/PD...
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by the clonal expansion of myeloid cells, notably megakaryocytes (MKs), and an aberrant cytokine production leading to bone marrow (BM) fibrosis insufficiency. Current treatment options are limited. TGF-β1, profibrotic immunosuppressive cytokine, involved in PMF pathogenesis. While all cell types secrete inactive, latent only few activate via type-specific mechanisms. The cellular source active TGF-β1 implicated not...
TPS5624 Background: Mucin-16 is a cell surface glycoprotein that overexpressed in epithelial ovarian cancer (OC). Ubamatamab (REGN4018) mucin-16 x cluster of differentiation 3 (MUC16xCD3) bispecific antibody promotes T cell–mediated cytotoxicity by facilitating contact between cells and cells. In mouse model studies, ubamatamab demonstrated dose-dependent antitumor activity against MUC16-expressing OC tumor 1 Cemiplimab an anti–programmed death-1 monoclonal antibody. Phase study...
<h3>Introduction</h3> Ubamatamab (REGN4018) is a MUC16xCD3 bispecific antibody that promotes T cell-mediated cytotoxicity by facilitating contact between cancer cells and cells. In Phase 1 study (NCT03564340) in patients with recurrent ovarian (OC), ubamatamab monotherapy demonstrated an acceptable safety profile durable clinical activity at doses of 20 mg to 800 IV weekly (by RECIST CA-125 response rates), linear pharmacokinetics up weekly. <h3>Methods</h3> 2, 150 advanced...
Abstract Background Subasumstat (TAK-981, suba) is a first-in-class innate immunity enhancer that unlocks innate/adaptive immune responses to target tumors through SUMOylation inhibition, which may enhance antitumor activity by restoring endogenous type 1 IFN signaling in cells. In the phase 1/2 study (NCT03648372), suba showed dose-dependent upregulation of an IFN-1 gene signature peripheral blood (PB) and plasma levels several IFN-1-induced cytokines, increase activated NK, CD8, CD4 T...
<title>Abstract</title> The increasing complexity of advanced-stage cancer management, coupled with the growing availability targeted therapies, necessitates innovative approaches to treatment decision-making. Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study evaluated feasibility and impact implementing comprehensive genomic profiling (CGP) across multiple laboratories integrating data into clinical decision-making patients advanced cancers. This prospective,...
<h3>Introduction</h3> Ubamatamab (REGN4018; mucin16 [MUC16] x CD3 bispecific antibody) promotes T-cell-mediated killing of ovarian cancer (OC) cells in preclinical studies. This activity is enhanced by the anti-PD-1 antibody cemiplimab. We present first-in-human ubamatamab +/- cemiplimab dose escalation results recurrent OC. <h3>Methods</h3> Patients with platinum-experienced OC received weekly intravenous 0.3–800 mg after step-up dosing. combination cohorts 350 every 3 weeks beginning Day...
<h3>Background</h3> The combination of an ATR inhibitor ceralasertib and anti-PD-L1 antibody durvalumab is being tested in Phase III clinical trials patients who have progressed on prior immunotherapy. Preclinical experiments were performed to build a greater understanding the potential immune driven mechanisms-of-action by which enhances antitumor efficacy with context dose schedule. <h3>Methods</h3> To assess associated pharmacodynamic effects was administered CT26 tumor-bearing BALB/c...
<h3>Background</h3> Multiple suppressive mechanisms within the tumor microenvironment are capable of blunting anti-tumor T cell responses, including engagement inhibitory receptors expressed in tumor-associated, exhausted CD8+ cells, such as programmed death protein 1 (PD-1), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), 2B4 (also known CD244), immunoreceptor with Ig ITIM domains (TIGIT).<sup>1 2</sup> While immune checkpoint blockade...
11554 Background: Breast carcinomas (BC) are often considered to be weakly immunogenic and thus poorly sensitive immunotherapy. Methods: We analyzed the repertoire of tumor-infiltrating T cells (TILs) in 41 early BC by sequencing their cell receptor β genes (TCRβ). Libraries were built using a digital approach, barcoding each sequenced molecule improve accuracy quantification. repertoires also obtained from paired blood samples allowing identification clones enriched tumors as compared...
<h3>Background</h3> Targeted immune-based therapies such as adoptive T cell transfer (ACT) are often ineffective because tumors evolve over time and under selective pressure display antigen loss variant clones. A classic example in melanoma is de-differentiation of expression antigenic proteins. Therapies that activate multiple branches the immune system may eliminate escape variants <h3>Methods</h3> Here we show melanoma-specific CD4+ ACT therapy combination with OX40 co-stimulation or...
Abstract BACKGROUD: The immunogenicity of some human tumors towards T lymphocytes is well established. Recently, encouraging results have been obtained with immunotherapies inhibiting immune checkpoints in cancers such as melanoma, NSCLC and bladder cancer. Fewer studies explored these treatments breast cancer (BC) are often considered to be poorly immunogenic. METHODS: We analysed the cell receptor β-chains variable genes (TCRBV) repertoires tumor-infiltrating cells 17 early BC. looked for...
Abstract Introduction While most transcripts arising from the human T Cell Receptor locus reflect fully rearranged genes, several germline have been identified. We describe a new transcript TCRB locus. Methods cDNA sequencing, promoter, and gene expression analyses were used to characterize transcript. Results The encoded by consists of exon 103 bp, which we named TRBX1 ( X1 ), spliced with first segments Cß1 or Cß2 . is located upstream segment Dß1 therefore deleted V‐DJ X1‐Cß do not appear...
Abstract Multiple suppressive mechanisms within the tumor microenvironment (TME) are capable of blunting anti-tumor T cell responses. These include engagement inhibitory receptors expressed in tumor-associated, exhausted CD8 cells, such as programmed death protein 1 (PD-1), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), 2B4 (also known CD244), immunoreceptor with Ig ITIM domains (TIGIT). While immune checkpoint blockade therapies aimed at...